Yoshiyuki Tsujihata
Takeda (Japan)(JP)
Publications by Year
Research Areas
Diabetes Treatment and Management, Pancreatic function and diabetes, Receptor Mechanisms and Signaling, Metabolism, Diabetes, and Cancer, Crystallization and Solubility Studies
Most-Cited Works
- → Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist(2010)247 cited
- → Visualizing and Modulating Mitophagy for Therapeutic Studies of Neurodegeneration(2020)170 cited
- → TAK-875, an Orally Available G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1 Agonist, Enhances Glucose-Dependent Insulin Secretion and Improves Both Postprandial and Fasting Hyperglycemia in Type 2 Diabetic Rats(2011)145 cited
- → A Novel Antidiabetic Drug, Fasiglifam/TAK-875, Acts as an Ago-Allosteric Modulator of FFAR1(2013)91 cited
- → Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists(2011)87 cited
- → The Effects of TAK-875, a Selective G Protein-Coupled Receptor 40/Free Fatty Acid 1 Agonist, on Insulin and Glucagon Secretion in Isolated Rat and Human Islets(2011)85 cited
- → Optimization of (2,3-Dihydro-1-benzofuran-3-yl)acetic Acids: Discovery of a Non-Free Fatty Acid-Like, Highly Bioavailable G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1 Agonist as a Glucose-Dependent Insulinotropic Agent(2012)73 cited
- → Identification of Fused-Ring Alkanoic Acids with Improved Pharmacokinetic Profiles that Act as G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1 Agonists(2012)64 cited
- → Discovery of Phenylpropanoic Acid Derivatives Containing Polar Functionalities as Potent and Orally Bioavailable G Protein-Coupled Receptor 40 Agonists for the Treatment of Type 2 Diabetes(2012)52 cited
- → Rapid and selective generation of H2S within mitochondria protects against cardiac ischemia-reperfusion injury(2022)37 cited